These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25835097)

  • 41. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis.
    Meinck HM; Schönle PW; Conrad B
    J Neurol; 1989 Feb; 236(2):120-2. PubMed ID: 2709054
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Study of the H reflex in spastic subjects treated with a GABA derivative (Ciba 34647-BA)].
    Fra L; Bergamini L; Brignolio F; Delsedime M
    Riv Neurol; 1971; 41(3):152-60. PubMed ID: 5126432
    [No Abstract]   [Full Text] [Related]  

  • 43. Marijuana and multiple sclerosis.
    Goodin D
    Lancet Neurol; 2004 Feb; 3(2):79-80. PubMed ID: 14746994
    [No Abstract]   [Full Text] [Related]  

  • 44. [Non-medicinal treatments of spasticity in multiple sclerosis].
    Mailhan L; Papeix C
    Rev Neurol (Paris); 2012 Apr; 168 Suppl 3():S57-61. PubMed ID: 22721366
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Cannabinoids in multiple sclerosis -- therapeutically reasonable?].
    Trebst C; Stangel M
    Fortschr Neurol Psychiatr; 2005 Aug; 73(8):463-9. PubMed ID: 16052440
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The use of repetitive transcranial magnetic stimulation (rTMS) for the treatment of spasticity.
    Mori F; Koch G; Foti C; Bernardi G; Centonze D
    Prog Brain Res; 2009; 175():429-39. PubMed ID: 19660671
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cryoanalgesia: a novel treatment for hip adductor spasticity and obturator neuralgia.
    Kim PS; Ferrante FM
    Anesthesiology; 1998 Aug; 89(2):534-6. PubMed ID: 9710418
    [No Abstract]   [Full Text] [Related]  

  • 48. [Symptomatic therapies for multiple sclerosis].
    Honda H
    Nihon Rinsho; 2003 Aug; 61(8):1355-60. PubMed ID: 12962023
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis.
    Wade DT; Collin C; Stott C; Duncombe P
    Mult Scler; 2010 Jun; 16(6):707-14. PubMed ID: 20558502
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Long-term treatment of spasticity with tisanidine (sirdulad) in 2 cases of multiple sclerosis].
    Cendrowski W
    Wiad Lek; 1987 Dec; 40(24):1711-4. PubMed ID: 3451608
    [No Abstract]   [Full Text] [Related]  

  • 51. Efficacy and safety of NT 201 for upper limb spasticity of various etiologies--a randomized parallel-group study.
    Barnes M; Schnitzler A; Medeiros L; Aguilar M; Lehnert-Batar A; Minnasch P
    Acta Neurol Scand; 2010 Oct; 122(4):295-302. PubMed ID: 20456248
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multiple sclerosis symptom management.
    Boissy AR; Cohen JA
    Expert Rev Neurother; 2007 Sep; 7(9):1213-22. PubMed ID: 17868019
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.
    Flachenecker P
    Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):15-9. PubMed ID: 23369055
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.
    Slof J; Ruiz L; Vila C
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):379-91. PubMed ID: 25771713
    [TBL] [Abstract][Full Text] [Related]  

  • 55. What is new in MS spasticity research? Poster session highlights.
    Kappos L; Fazekas F
    Neurodegener Dis Manag; 2015; 5(6 Suppl):27-30. PubMed ID: 26611269
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Country break-out session highlights.
    Fazekas F; Gehring K; Gallo P; Lebrun-Frénay C; Moral E; Myhr KM
    Neurodegener Dis Manag; 2015; 5(6 Suppl):31-7. PubMed ID: 26611270
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiple sclerosis spasticity epidemiology--key publications.
    Gold R
    Expert Rev Neurother; 2013 Dec; 13(12 Suppl):45-6. PubMed ID: 24289842
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Conclusion].
    Bensmail D
    Rev Neurol (Paris); 2012 Apr; 168 Suppl 3():S69. PubMed ID: 22721368
    [No Abstract]   [Full Text] [Related]  

  • 59. [Medicinal cannabis for diseases of the nervous system: no convincing evidence of effectiveness].
    Killestein J; Bet PM; van Loenen AC; Polman CH
    Ned Tijdschr Geneeskd; 2004 Nov; 148(48):2374-8. PubMed ID: 15615271
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.
    Pozzilli C
    Expert Rev Neurother; 2013 Dec; 13(12 Suppl):49-54. PubMed ID: 24289844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.